NASDAQ:KURA
Kura Oncology Stock News
$21.01
+0.380 (+1.84%)
At Close: May 06, 2024
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
07:00am, Wednesday, 24'th Feb 2021
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Participate in Four Upcoming Investor Conferences
07:30am, Thursday, 18'th Feb 2021
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
07:30am, Wednesday, 17'th Feb 2021
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
07:30am, Thursday, 07'th Jan 2021
– Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb – – Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott G
Kura Oncology to Present at J.P. Morgan Healthcare Conference
07:30am, Wednesday, 06'th Jan 2021
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
04:05pm, Friday, 11'th Dec 2020
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
01:45pm, Thursday, 10'th Dec 2020
Kura Oncology looks an attractive opportunity in the Precision Medicine / Targeted Therapies sector.
Kura Oncology to Participate in the JMP Securities Hematology Summit
07:30am, Thursday, 10'th Dec 2020
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
08:22pm, Tuesday, 08'th Dec 2020
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Commencement of Public Offering of Common Stock
04:01pm, Monday, 07'th Dec 2020
SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
12:30pm, Saturday, 05'th Dec 2020
– Evidence of biologic activity observed in each dose-escalation cohort treated to date –
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript
01:21pm, Saturday, 07'th Nov 2020
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript
Kura Oncology to Participate in Three Upcoming Investor Conferences
07:30am, Wednesday, 04'th Nov 2020
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Report Third Quarter 2020 Financial Results
07:30am, Thursday, 29'th Oct 2020
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
